DOCSLIB.ORG

PHASE VII Annex 01- National Master List of Drugs &Lab Reagents

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
PHASE VII Annex 01- National Master List of Drugs &Lab Reagents PHASE VII Annex 01- National Master List of Drugs &Lab Reagents Important Note:All human products must be of human recombinant origin wherever these are available in the market MOH CODE ITEM NAME 1 CARDIOVASCULAR SYSTEM 1A DIGITALIS GLYCOSIDE 02-01-00001 digoxin tab 62.5 mcg 651300 02-01-00002 digitoxin tab 100 mcg 651300 02-01-00003 digoxin tab 125 mcg 651300 02-01-00004 digoxin tab 250 mcg 14300000 02-01-00005 digoxin PG elixir 50mcg /ml 651300 02-01-00006 digoxin inj 250 mcg/ml, (2ml amp) 651300 1B DIURETICS 02-01-00007 amiloride Hcl 5mg + hydrochlorthiazide 50mg tab 48750000 02-01-00008 bumetanide tab 1 mg 1014000 02-01-00009 chlorthalidone tab 50mg 3162900 02-01-00010 ethacrynic acid as sod.salt inj powder for reconstitution 50mg vial 651300 02-01-00011 frusemide inj 20mg/2ml amp 3900000 02-01-00012 frusemide IV infusion inj 10mg/ml, 25ml amp 819000 02-01-00013 frusemide tab 40mg 26000000 02-01-00014 frusemide scored tab 500mg 651300 02-01-00015 frusemide oral solution pead liquid 1mg/1ml 651300 02-01-00016 frusemide oral solution 4mg/ml 651300 02-01-00017 frusemide oral solution 8mg/ml 651300 02-01-00018 hydrochlorothiazide tab 25mg 1232400 02-01-00019 hydrochlorothiazide tab 50mg 2566200 02-01-00020 indapamide tab 2.5m g 651300 02-01-00021 spironolactone tab 25mg 3900000 02-01-00022 spironolactone tab 100mg 3900000 02-01-00023 Xipamide tab 20mg 659100 1C BETA-ADRENOCEPTER BLOCKING DRUGS 02-01-00024 acebutolol tab 100mg 655200 02-01-00025 acebutolol tab 200mg 651300 02-01-00026 atenolol tab 100mg 94900000 02-01-00027 atenolol tab 50mg or scored tab 19500000 02-01-00028 atenolol tab 25mg 663780 02-01-00029 Bisoprolol fumarate scored tab 5mg 670800 02-01-00030 Bisoprolol fumarate scored tab 10mg 674700 02-01-00031 Carvedilol 6.25mg tab 670800 02-01-00032 Carvedilol 12.5mg tab 678600 02-01-00033 Carvedilol 25mg tab 670800 02-01-00034 Esmolol Hcl IV infusion 10mg/ml (10ml vial) 651300 02-01-00035 labetalol inj 5mg/ml (20ml amp) 651300 02-01-00036 labetalol tab 200mg 651300 02-01-00037 labetalol tab 400mg 670800 02-01-00038 metoprolol tab 50mg 651300 02-01-00039 metoprolol tab (s/r) 200mg 1020240 02-01-00040 metoprolol tartrate IV inj 1mg/ml (5ml amp) 651300 02-01-00041 nadolol tab 80mg 651300 02-01-00042 oxprenolol Hcl tab 40mg 651300 02-01-00043 pindolol tab 5mg 1458600 02-01-00044 propranolol Hcl slow IV inj 1mg/ml (1ml amp) 651300 02-01-00045 propranolol Hcl tab 10mg 18200000 02-01-00046 propranolol Hcl tab (or scored tab) 40mg 48100000 02-01-00047 propranolol Hcl cap (s/r) 80mg 651300 02-01-00048 sotalol tab 40mg 659100 MOH CODE ITEM NAME 02-01-00049 sotalol tab 80mg 659100 1D ANTI-ARRHYTHMIC DRUGS 02-01-00050 amiodarone Hcl inj 50mg/ml (3ml amp) 651300 02-01-00051 Amiodarone Hcl 200mg tab. 3250000 02-01-00052 bretylium tosylate inj 50mg/ml,( 10ml amp) 651300 02-01-00053 disopyramide caps 100mg 1950000 02-01-00054 disopyramide tab (s/r) durules 150mg 651300 02-01-00055 disopyramide tab retard (s/r) 250mg 651300 02-01-00056 disopyramide inj 10mg/ml, (5ml amp) 651300 02-01-00057 lignocaine Hcl slow iv infusion inj 20mg/ml, (50ml vial) plain 651300 02-01-00058 lignocaine Hcl inj 50mg/ml, (2ml amp) Spinal 664950 02-01-00059 mexiletine Hcl caps 50mg 2106000 02-01-00060 mexiletine Hcl caps 200mg 3250000 02-01-00061 mexiletine Hcl IV,IV infusion inj 25mg/ml, (10ml amp) 651300 02-01-00062 phenytoin sod.inj 50mg/ml, (5ml amp) 651300 02-01-00063 practolol inj 2mg/ml, (5ml amp) 651300 02-01-00064 procainamide Hcl slow IV, IV infusion inj 100mg/ml, (10ml vial) 651300 02-01-00065 procainamide Hcl tab 500mg 659100 02-01-00066 procainamide Hcl tab (s/r) 750mg 651300 02-01-00067 propafenon Hcl tab 150mg 651300 02-01-00068 quinidine Bisulfate tab (s/r) 250mg (Durules) 651300 02-01-00069 quinidine Sulphate tab 200mg 651300 02-01-00070 verapamil Hcl inj 2.5mg/ml, (2ml amp) 668850 02-01-00071 verapamil Hcl tab 40mg 3250000 02-01-00072 verapamil Hcl tab 80mg 1034670 02-01-00073 verapamil Hcl tab (s/r) 120mg or cap, 663000 1E ANTI-HYPERTENSIVE DRUGS 02-01-00074 alfuzosin Hcl tab 2.5mg 1953900 02-01-00075 alfuzosin Hcl (S/R) tab 5mg 651300 02-01-00076 captopril tab 25mg 73450000 02-01-00077 captopril tab 50mg 46800000 02-01-00078 diazoxide tab 50mg 741000 02-01-00079 doxazosin scored tab 2mg 5200000 02-01-00080 enalapril tab 5mg 694200 02-01-00081 enalapril tab 10mg 846300 02-01-00082 enalapril tab 20mg 728520 02-01-00083 hydralazine Hcl IV infusion inj 20mg per amp 668850 02-01-00084 hydralazine Hcl tab 25mg 1605630 02-01-00085 hydralazine Hcl tab 50mg 776100 02-01-00086 Lisinopril tab 5mg 694200 02-01-00087 Lisinopril tab 10mg 733200 02-01-00088 Lisinopril tab 20mg 694200 02-01-00089 Losartan potassium tab 50mg 686400 02-01-00090 methyldopa inj 50mg/ml, (5ml amp) 663780 02-01-00091 methyldopa tab 250mg 68900000 02-01-00092 minoxidil tab 5mg 651300 02-01-00093 minoxidil tab 10mg 655200 02-01-00094 phenoxybenzamine Hcl caps 10mg 690300 02-01-00095 phenoxybenzamine Hcl inj 50mg/ml, (2ml amp) 651300 02-01-00096 phentolamine mesylate inj 10mg/ml, (1ml amp) 651300 02-01-00097 prazosin Hcl tab 0.5mg 651300 02-01-00098 prazosin Hcl tab or scored tab 1mg 674700 02-01-00099 prazosin Hcl tab 2mg 659100 02-01-00100 prazosin Hcl tab 5mg 760500 02-01-00101 Quinapril Hcl tab 5mg 678600 02-01-00102 Quinapril Hcl tab 10mg 678600 MOH CODE ITEM NAME 02-01-00103 Quinapril Hcl tab 20mg 678600 02-01-00104 reserpine tab 100mcg 651300 02-01-00105 sodium nitroprusside i.v.inf 50mg per amp with solvent 651300 02-01-00106 tolazolin Hcl inj i.v 651300 02-01-00107 Valsartan cap 160mg 2384850 02-01-00108 Valsartan cap 40mg 2388750 02-01-00109 Valsartan cap 80mg 2472600 02-01-00110 Telmisartan 40mg tab 663000 02-01-00111 Telmisartan 80mg tab 663000 1F VASODILATORS 02-01-00112 Amlodipine (as besylate) tab 2.5mg 651300 02-01-00113 Amlodipine (as besylate) tab 5mg 678600 02-01-00114 Amlodipine (as besylate) tab 10mg 659100 02-01-00115 cinnarizine tab 25mg 14950000 02-01-00116 cinnarizine 75mg cap or tab 2394600 02-01-00117 diltiazem Hcl tab 60mg 8450000 02-01-00118 diltiazem Hcl cap (s/r) 90mg 8450000 02-01-00119 diltiazem Hcl cap (s/r) 120mg 8450000 02-01-00120 diltiazem Hcl IV inj or infusion 25mg/vial 651690 02-01-00121 Felodipine 5mg tab 663000 02-01-00122 glyceryl trinitrate tab 0. 5mg 59800000 02-01-00123 glyceryl trinitrate inj 5mg/10ml amp. 651690 02-01-00124 glyceryl trinitrate plaster 5mg 659100 02-01-00125 glyceryl trinitrate plaster 10mg 659100 02-01-00126 glyceryl trinitrate plaster 15mg 659100 02-01-00127 glyceryl trinitrate plaster 25mg 659100 02-01-00128 glyceryl trinitrate spray 652860 02-01-00129 glyceryl trinitrate tab (c/r) 2.6mg 651300 02-01-00130 glyceryl trinitrate tab (c/r) 6.4mg 651300 02-01-00131 isosorbide dinitrate tab (s/l) 5mg 14300000 02-01-00132 isosorbide dinitrate tab 10mg 107900000 02-01-00133 isosorbide dinitrate tab (s/r) 20mg or cap 889200 02-01-00134 isosorbide dinitrate tab (s/r) 40mg 651300 02-01-00135 isosorbide mononitrate tab 10mg 2730000 02-01-00136 isosorbide mononitrate tab or cap 20mg 1205100 02-01-00137 Isosorbide mononitrate 40 mg tab 651300 02-01-00138 Isosorbide mononitrate 60 mg tab 651300 02-01-00139 isosorbide mononitrate tab(s/r)25mg or cap 651300 02-01-00140 isosorbide mononitrate tab(s/r)50mg or cap 651300 02-01-00141 Nicardipine Hcl IV inj 25mg (solution)/ amp 651300 02-01-00142 nifedipine caps 5mg 686010 02-01-00143 nifedipine caps 10mg 84500000 02-01-00144 nifedipine (s/r) caps or tab 10mg 651300 02-01-00145 nifedipine caps (s/r) 20mg 9750000 02-01-00146 nifedipine caps or tab (s/r) 30mg (24hr) 651300 02-01-00147 nifedipine caps (s/r) 60mg (24hr) 651300 02-01-00148 nimodipine tab 30mg 1139190 02-01-00149 nimodipine i.v infusion 200mcg/ml (50ml vial) 652470 02-01-00150 oxpentiphylline tab 400mg (pentoxifylline) 2312700 02-01-00151 oxpentiphylline tab 600mg (pentoxifylline) 1875900 1G SYMPATHOMIMETIC DRUGS 02-01-00152 dobutamine Hcl inj 250mg per vial 651300 02-01-00153 dopamine Hcl inj 40mg/ml, (5ml amp) 651300 02-01-00154 isoprenaline Hcl inj 200 mcg/ml, (5ml amp) 651300 02-01-00155 isoprenaline Hcl tab (s/r) 20mg 651300 02-01-00156 metaraminol (as tartrate) inj 10mg/ml, (1ml amp) 651300 MOH CODE ITEM NAME 02-01-00157 methoxamine Hcl inj 20mg/ml, (1ml amp) 651300 02-01-00158 phenylephrine Hcl inj 10mg/ml, (1ml amp) 651300 1H SCLEROSING AGENTS 02-01-00159 ethanolamine oleate inj 5% 651300 02-01-00160 Sodium tetradecyl sulphate 3% (1ml amp) 651300 1I PHOSPHODIESTERASE INHIBITORS 02-01-00161 Enoximone inj 5mg/1ml (20ml amp) 651300 2 GASTRO-INTESTINAL SYSTEM 2A ANTACIDS 02-01-00162 alginic acid 500mg + mag.trisilicate 25mg + dried Al.hydroxide gel 100mg 57850000 +sod.bicarb.170mg tab 02-01-00163 Al.hydroxide 215mg +mag.hydroxide 80mg + simethicone 25mg/5ml susp 2525250 02-01-00164 Al.hydroxide 225mg + mag.hydroxide 200mg + simethicone 25mg/5ml 2252250 susp 02-01-00165 Al hydroxide dried gel 475 mg tab 29900000 02-01-00166 Aluminium hydroxide 140mg+mag.trisilicate 140mg+mag.carbonate 452mg 3250000 (or 560mg)+bismuth subcarbonate 73mg +sod.bicarbonate 452mg +malt diastase 28mg+belladona alkaloids 70mcg(or 75mcg) /teaspoonful powder 02-01-00167 co-dried mag.carb.Al.hydroxide 282 + simethicone 25mg tab 13650000 02-01-00168 colloidal aluminium hydroxide tab 440mg 9750000 02-01-00169 colloidal aluminium hydroxide susp 290mg/5ml, 1957800 02-01-00170 dried Al.hydroxide gel 200mg +mag.hydroxide 200mg+simethicone 25mg 27105000 tab 02-01-00171 magnesium trisilicate powder B.P 651300 02-01-00172 Mg trisilicate 250mg+dried Al.hydroxide gel 120mg tab 7150000 02-01-00173 Mg trisilicate 360mg + Al hydroxide gel 180mg tab 30550000 02-01-00174 Mg trisilicate 200mg + Al hydroxide mag.
Load more

Recommended publications
  • Drug-Induced Anaphylaxis in China: a 10 Year Retrospective Analysis of The
    Int J Clin Pharm DOI 10.1007/s11096-017-0535-2 RESEARCH ARTICLE Drug‑induced anaphylaxis in China: a 10 year retrospective analysis of the Beijing Pharmacovigilance Database Ying Zhao1,2,3 · Shusen Sun4 · Xiaotong Li1,3 · Xiang Ma1 · Huilin Tang5 · Lulu Sun2 · Suodi Zhai1 · Tiansheng Wang1,3,6 Received: 9 May 2017 / Accepted: 19 September 2017 © The Author(s) 2017. This article is an open access publication Abstract Background Few studies on the causes of (50.1%), mucocutaneous (47.4%), and gastrointestinal symp- drug-induced anaphylaxis (DIA) in the hospital setting are toms (31.3%). A total of 249 diferent drugs were involved. available. Objective We aimed to use the Beijing Pharma- DIAs were mainly caused by antibiotics (39.3%), traditional covigilance Database (BPD) to identify the causes of DIA Chinese medicines (TCM) (11.9%), radiocontrast agents in Beijing, China. Setting Anaphylactic case reports from (11.9%), and antineoplastic agents (10.3%). Cephalospor- the BPD provided by the Beijing Center for Adverse Drug ins accounted for majority (34.5%) of antibiotic-induced Reaction Monitoring. Method DIA cases collected by the anaphylaxis, followed by fuoroquinolones (29.6%), beta- BPD from January 2004 to December 2014 were adjudi- lactam/beta-lactamase inhibitors (15.4%) and penicillins cated. Cases were analyzed for demographics, causative (7.9%). Blood products and biological agents (3.1%), and drugs and route of administration, and clinical signs and plasma substitutes (2.1%) were also important contributors outcomes. Main outcome measure Drugs implicated in DIAs to DIAs. Conclusion A variety of drug classes were impli- were identifed and the signs and symptoms of the DIA cases cated in DIAs.
    [Show full text]
  • Page 1 Note: Within Nine Months from the Publication of the Mention
    Europäisches Patentamt (19) European Patent Office & Office européen des brevets (11) EP 1 411 992 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61K 49/04 (2006.01) A61K 49/18 (2006.01) 13.12.2006 Bulletin 2006/50 (86) International application number: (21) Application number: 02758379.8 PCT/EP2002/008183 (22) Date of filing: 23.07.2002 (87) International publication number: WO 2003/013616 (20.02.2003 Gazette 2003/08) (54) IONIC AND NON-IONIC RADIOGRAPHIC CONTRAST AGENTS FOR USE IN COMBINED X-RAY AND NUCLEAR MAGNETIC RESONANCE DIAGNOSTICS IONISCHES UND NICHT-IONISCHES RADIOGRAPHISCHES KONTRASTMITTEL ZUR VERWENDUNG IN DER KOMBINIERTEN ROENTGEN- UND KERNSPINTOMOGRAPHIEDIAGNOSTIK SUBSTANCES IONIQUES ET NON-IONIQUES DE CONTRASTE RADIOGRAPHIQUE UTILISEES POUR ETABLIR DES DIAGNOSTICS FAISANT APPEL AUX RAYONS X ET A L’IMAGERIE PAR RESONANCE MAGNETIQUE (84) Designated Contracting States: (74) Representative: Minoja, Fabrizio AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Bianchetti Bracco Minoja S.r.l. IE IT LI LU MC NL PT SE SK TR Via Plinio, 63 20129 Milano (IT) (30) Priority: 03.08.2001 IT MI20011706 (56) References cited: (43) Date of publication of application: EP-A- 0 759 785 WO-A-00/75141 28.04.2004 Bulletin 2004/18 US-A- 5 648 536 (73) Proprietor: BRACCO IMAGING S.p.A. • K HERGAN, W. DORINGER, M. LÄNGLE W.OSER: 20134 Milano (IT) "Effects of iodinated contrast agents in MR imaging" EUROPEAN JOURNAL OF (72) Inventors: RADIOLOGY, vol. 21, 1995, pages 11-17, • AIME, Silvio XP002227102 20134 Milano (IT) • K.M.
    [Show full text]
  • ACR Manual on Contrast Media
    ACR Manual On Contrast Media 2021 ACR Committee on Drugs and Contrast Media Preface 2 ACR Manual on Contrast Media 2021 ACR Committee on Drugs and Contrast Media © Copyright 2021 American College of Radiology ISBN: 978-1-55903-012-0 TABLE OF CONTENTS Topic Page 1. Preface 1 2. Version History 2 3. Introduction 4 4. Patient Selection and Preparation Strategies Before Contrast 5 Medium Administration 5. Fasting Prior to Intravascular Contrast Media Administration 14 6. Safe Injection of Contrast Media 15 7. Extravasation of Contrast Media 18 8. Allergic-Like And Physiologic Reactions to Intravascular 22 Iodinated Contrast Media 9. Contrast Media Warming 29 10. Contrast-Associated Acute Kidney Injury and Contrast 33 Induced Acute Kidney Injury in Adults 11. Metformin 45 12. Contrast Media in Children 48 13. Gastrointestinal (GI) Contrast Media in Adults: Indications and 57 Guidelines 14. ACR–ASNR Position Statement On the Use of Gadolinium 78 Contrast Agents 15. Adverse Reactions To Gadolinium-Based Contrast Media 79 16. Nephrogenic Systemic Fibrosis (NSF) 83 17. Ultrasound Contrast Media 92 18. Treatment of Contrast Reactions 95 19. Administration of Contrast Media to Pregnant or Potentially 97 Pregnant Patients 20. Administration of Contrast Media to Women Who are Breast- 101 Feeding Table 1 – Categories Of Acute Reactions 103 Table 2 – Treatment Of Acute Reactions To Contrast Media In 105 Children Table 3 – Management Of Acute Reactions To Contrast Media In 114 Adults Table 4 – Equipment For Contrast Reaction Kits In Radiology 122 Appendix A – Contrast Media Specifications 124 PREFACE This edition of the ACR Manual on Contrast Media replaces all earlier editions.
    [Show full text]
  • Estonian Statistics on Medicines 2016 1/41
    Estonian Statistics on Medicines 2016 ATC code ATC group / Active substance (rout of admin.) Quantity sold Unit DDD Unit DDD/1000/ day A ALIMENTARY TRACT AND METABOLISM 167,8985 A01 STOMATOLOGICAL PREPARATIONS 0,0738 A01A STOMATOLOGICAL PREPARATIONS 0,0738 A01AB Antiinfectives and antiseptics for local oral treatment 0,0738 A01AB09 Miconazole (O) 7088 g 0,2 g 0,0738 A01AB12 Hexetidine (O) 1951200 ml A01AB81 Neomycin+ Benzocaine (dental) 30200 pieces A01AB82 Demeclocycline+ Triamcinolone (dental) 680 g A01AC Corticosteroids for local oral treatment A01AC81 Dexamethasone+ Thymol (dental) 3094 ml A01AD Other agents for local oral treatment A01AD80 Lidocaine+ Cetylpyridinium chloride (gingival) 227150 g A01AD81 Lidocaine+ Cetrimide (O) 30900 g A01AD82 Choline salicylate (O) 864720 pieces A01AD83 Lidocaine+ Chamomille extract (O) 370080 g A01AD90 Lidocaine+ Paraformaldehyde (dental) 405 g A02 DRUGS FOR ACID RELATED DISORDERS 47,1312 A02A ANTACIDS 1,0133 Combinations and complexes of aluminium, calcium and A02AD 1,0133 magnesium compounds A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 811120 pieces 10 pieces 0,1689 A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 3101974 ml 50 ml 0,1292 A02AD83 Calcium carbonate+ Magnesium carbonate (O) 3434232 pieces 10 pieces 0,7152 DRUGS FOR PEPTIC ULCER AND GASTRO- A02B 46,1179 OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 2,3855 A02BA02 Ranitidine (O) 340327,5 g 0,3 g 2,3624 A02BA02 Ranitidine (P) 3318,25 g 0,3 g 0,0230 A02BC Proton pump inhibitors 43,7324 A02BC01 Omeprazole
    [Show full text]
  • EUROPEAN PHARMACOPOEIA 10.0 Index 1. General Notices
    EUROPEAN PHARMACOPOEIA 10.0 Index 1. General notices......................................................................... 3 2.2.66. Detection and measurement of radioactivity........... 119 2.1. Apparatus ............................................................................. 15 2.2.7. Optical rotation................................................................ 26 2.1.1. Droppers ........................................................................... 15 2.2.8. Viscosity ............................................................................ 27 2.1.2. Comparative table of porosity of sintered-glass filters.. 15 2.2.9. Capillary viscometer method ......................................... 27 2.1.3. Ultraviolet ray lamps for analytical purposes............... 15 2.3. Identification...................................................................... 129 2.1.4. Sieves ................................................................................. 16 2.3.1. Identification reactions of ions and functional 2.1.5. Tubes for comparative tests ............................................ 17 groups ...................................................................................... 129 2.1.6. Gas detector tubes............................................................ 17 2.3.2. Identification of fatty oils by thin-layer 2.2. Physical and physico-chemical methods.......................... 21 chromatography...................................................................... 132 2.2.1. Clarity and degree of opalescence of
    [Show full text]
  • The Risk of Contrast Media-Induced Ventricular Fibrillation Is Low in Canine Coronary Arteriography with Ioxilan
    FULL PAPER Surgery The Risk of Contrast Media-Induced Ventricular Fibrillation is Low in Canine Coronary Arteriography with Ioxilan Kazuhiro MISUMI, Oki TATENO, Makoto FUJIKI, Naoki MIURA and Hiroshi SAKAMOTO Department of Veterinary Medicine, Kagoshima University, 21–24 Korimoto 1-chome, Kagoshima 890–0065, Japan (Received 5 August 1999/Accepted 28 December 1999) ABSTRACT. Previous studies have proposed that sodium supplement to nonionic contrast media (CM) can decrease the risk of ventricular fibrillation (VF). This study was designed to compare the occurence of VF induced by ioxilan (containing 9 mmol/LNa+) with other nonionic CMs. After wedging a catheter in the right coronary artery, test solutions including ioxilan, ioversol, iomeprol, and iopromide were infused for 30 sec at the rate of 0.4 ml/sec or until VF occurred. Then, incidence of VF, contact time (i.e. the time required to produce VF), and QTc were measured. Also, the CMs other than ioxilan were investigated at sodium levels adjusted to 9 and 20 mmol/L Na+. The incidence of VF with ioxilan (0% ) was the lowest of all. In the other CMs, the incidence decreased in accordance with increase of sodium. Iomeprol and iopromide showed significant reduction of VF incidence at the sodium level of 20 mmol/L. The higher sodium supplements also prolonged the contact times. The increase of QTc was the greatest in ioxilan. Ioxilan has the least arrythmogenic property among the current low-osmolality nonionic CMs. This property might be attributable to an optimal sodium concentration of 9 mmol/L in the CM.—KEY WORDS: contrast media, coronary arteriography, ioxilan, ventricular fibrillation.
    [Show full text]
  • Alphabetical Listing of ATC Drugs & Codes
    Alphabetical Listing of ATC drugs & codes. Introduction This file is an alphabetical listing of ATC codes as supplied to us in November 1999. It is supplied free as a service to those who care about good medicine use by mSupply support. To get an overview of the ATC system, use the “ATC categories.pdf” document also alvailable from www.msupply.org.nz Thanks to the WHO collaborating centre for Drug Statistics & Methodology, Norway, for supplying the raw data. I have intentionally supplied these files as PDFs so that they are not quite so easily manipulated and redistributed. I am told there is no copyright on the files, but it still seems polite to ask before using other people’s work, so please contact <[email protected]> for permission before asking us for text files. mSupply support also distributes mSupply software for inventory control, which has an inbuilt system for reporting on medicine usage using the ATC system You can download a full working version from www.msupply.org.nz Craig Drown, mSupply Support <[email protected]> April 2000 A (2-benzhydryloxyethyl)diethyl-methylammonium iodide A03AB16 0.3 g O 2-(4-chlorphenoxy)-ethanol D01AE06 4-dimethylaminophenol V03AB27 Abciximab B01AC13 25 mg P Absorbable gelatin sponge B02BC01 Acadesine C01EB13 Acamprosate V03AA03 2 g O Acarbose A10BF01 0.3 g O Acebutolol C07AB04 0.4 g O,P Acebutolol and thiazides C07BB04 Aceclidine S01EB08 Aceclidine, combinations S01EB58 Aceclofenac M01AB16 0.2 g O Acefylline piperazine R03DA09 Acemetacin M01AB11 Acenocoumarol B01AA07 5 mg O Acepromazine N05AA04
    [Show full text]
  • Premedication for Contrast Medium Allergies Factfinder
    Published March 2014 Premedication for Contrast Medium Allergies FactFinder Committed to providing helpful information to International Spine Intervention Society members about key patient safety issues, the Society’s Patient Safety Committee has developed a FactFinder series. FactFinders will explore and debunk myths surrounding patient safety issues. The intent of this FactFinder is to present the evidence regarding the effectiveness of premedication for contrast medium allergies that impact the delivery of spinal procedures. Myth #1: In patients with radiocontrast media (RCM) allergy, it is safe to proceed with RCM injection as long as the patient is premedicated with steroids and antihistamines. Fact: Although premedication likely reduces the risks associated with injecting RCM, no premedication regimen has been proven safe for a RCM allergic reaction. Conclusions & Recommendations The International Spine Intervention Society Guidelines recommend the use of RCM for nearly all spinal diagnostic and treatment procedures.1 An understanding of the severity and frequency of reactions to RCM is paramount prior to discussing premedication. Reactions to RCM are immediate, defined as within the first hour, with 70% occurring within the first five minutes; or late, occurring between one hour and one week later. The late reactions are typically cutaneous.2 There are three types of immediate reactions: mild, moderate, and severe. Mild reactions: include nausea, vomiting, and mild urticaria. These signs and symptoms appear self-limited without evidence of progression. Treatment usually entails only observation and reassurance, however, these reactions may progress into a more severe category. Moderate reactions: include moderate urticaria, vasovagal reaction, mild bronchospasm, and tachycardia. These reactions require treatment, but are not immediately life threatening.
    [Show full text]
  • Estonian Statistics on Medicines 2013 1/44
    Estonian Statistics on Medicines 2013 DDD/1000/ ATC code ATC group / INN (rout of admin.) Quantity sold Unit DDD Unit day A ALIMENTARY TRACT AND METABOLISM 146,8152 A01 STOMATOLOGICAL PREPARATIONS 0,0760 A01A STOMATOLOGICAL PREPARATIONS 0,0760 A01AB Antiinfectives and antiseptics for local oral treatment 0,0760 A01AB09 Miconazole(O) 7139,2 g 0,2 g 0,0760 A01AB12 Hexetidine(O) 1541120 ml A01AB81 Neomycin+Benzocaine(C) 23900 pieces A01AC Corticosteroids for local oral treatment A01AC81 Dexamethasone+Thymol(dental) 2639 ml A01AD Other agents for local oral treatment A01AD80 Lidocaine+Cetylpyridinium chloride(gingival) 179340 g A01AD81 Lidocaine+Cetrimide(O) 23565 g A01AD82 Choline salicylate(O) 824240 pieces A01AD83 Lidocaine+Chamomille extract(O) 317140 g A01AD86 Lidocaine+Eugenol(gingival) 1128 g A02 DRUGS FOR ACID RELATED DISORDERS 35,6598 A02A ANTACIDS 0,9596 Combinations and complexes of aluminium, calcium and A02AD 0,9596 magnesium compounds A02AD81 Aluminium hydroxide+Magnesium hydroxide(O) 591680 pieces 10 pieces 0,1261 A02AD81 Aluminium hydroxide+Magnesium hydroxide(O) 1998558 ml 50 ml 0,0852 A02AD82 Aluminium aminoacetate+Magnesium oxide(O) 463540 pieces 10 pieces 0,0988 A02AD83 Calcium carbonate+Magnesium carbonate(O) 3049560 pieces 10 pieces 0,6497 A02AF Antacids with antiflatulents Aluminium hydroxide+Magnesium A02AF80 1000790 ml hydroxide+Simeticone(O) DRUGS FOR PEPTIC ULCER AND GASTRO- A02B 34,7001 OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 3,5364 A02BA02 Ranitidine(O) 494352,3 g 0,3 g 3,5106 A02BA02 Ranitidine(P)
    [Show full text]
  • Muscular and CNS Effects of Carotid Artery Administration of Contrast Media in Rabbits
    143 Muscular and CNS Effects of Carotid Artery Administration of Contrast Media in Rabbits Christopher C. Whisson 1 Facial muscle twitching during intracarotid injections of nonionic contrast media has Charles A. Evill been observed in rabbits. To investigate the cause of this reaction, cortical EEG and Michael R. Sage facial EMG recordings were made from rabbits receiving selective internal and external Alan J . Wilson carotid artery injections of control solutions (normal saline, mannitol), an ionic contrast medium (meglumine iothalamate), and three nonionic contrast media (iohexol, iopro­ mide, ::tnd iotrolan). Internal carotid artery injections with all contrast media, both ionic and nonionic, produced ipsilateral EEG changes in 24 of 28 animals; however, ipsilateral EMG changes and visible twitching were observed only in animals injected with nonionic contrast media. Internal carotid artery injections with control ionic and nonionic solutions (physiological saline and mannitol, respectively) produced no EEG changes in any animals. Mannitol produced only ipsilateral EMG changes and visible twitching in most animals. The severity of the reaction to mannitol was generally less than that to the nonionic contrast media, and this difference was statistically significant when comparing mannitol with iohexol and iotrolan but not with iopromide. External carotid artery injections with nonionic solutions (contrast media and mannitol) produced significantly more severe ipsilateral EMG changes and visible twitching than were recorded with the internal carotid artery injections. Ionic solutions (contrast media and saline) had no effect. EEG changes were not observed after external carotid artery injection of any solution, with the exception of two of the seven animals injected with iotrolan. Angiog­ raphy demonstrated retrograde filling of the external carotid arterial system from internal carotid artery injection via functioning orbital anastamoses.
    [Show full text]
  • Immediate Reactions Following Iodinated Contrast Media Injection: a Study of 38 Cases
    European Journal of Radiology 77 (2011) 495–501 Contents lists available at ScienceDirect European Journal of Radiology journal homepage: www.elsevier.com/locate/ejrad Immediate reactions following iodinated contrast media injection: A study of 38 cases Pascale Dewachter a,∗, Dominique Laroche b,1, Claudie Mouton-Faivre c,2, Evelyne Bloch-Morot d,3, Jean-Pierre Cercueil e,4, Liliane Metge f,5, Marie-France Carette g,6, Marie-Claude Vergnaud h,7, Olivier Clément i,8 a Service d’Anesthésie-Réanimation Chirurgicale & SAMU de Paris, Hôpital Necker-Enfants Malades, AP-HP, Université Paris-Descartes, 149 Rue de Sèvres, 75015 Paris, France b Service de Biophysique, Centre Hospitalier Universitaire, Avenue de la Côte de Nacre, Caen, France c Pôle d’Anesthésie-Réanimation Chirurgicale, Centre Hospitalier Universitaire-Hôpital Central, Avenue du Maréchal de Lattre de Tassigny, Nancy, France d Service de Médecine Interne, Hôpital Européen Georges Pompidou, 20 Rue Leblanc, Paris, France e Département d’Imagerie Medicale, Centre Hospitalier Universitaire, Hôpital du Bocage, 2, Boulevard du Maréchal de Lattre de Tassigny, Dijon, France f Département d’Imagerie Médicale, Centre Hospitalier Universitaire Caremeau, Place du Pr Robert Debré, Nîmes, France g Service de Radiologie, Hôpital Tenon, 4 Rue de la Chine, Paris, France h Service de Médecine Polyvalente, Centre Hospitalier Universitaire, Avenue de la Côte de Nacre, Caen, France i Service de Radiologie, Hôpital Européen Georges Pompidou, AP-HP, Université Paris Descartes, 20 Rue Leblanc, Paris, France article info abstract Article history: Objectives: To investigate the pathomechanisms involved in cases of immediate hypersensitivity reactions Received 2 August 2009 occurring after the administration of iodinated contrast media.
    [Show full text]
  • FDA Listing of Established Pharmacologic Class Text Phrases January 2021
    FDA Listing of Established Pharmacologic Class Text Phrases January 2021 FDA EPC Text Phrase PLR regulations require that the following statement is included in the Highlights Indications and Usage heading if a drug is a member of an EPC [see 21 CFR 201.57(a)(6)]: “(Drug) is a (FDA EPC Text Phrase) indicated for Active Moiety Name [indication(s)].” For each listed active moiety, the associated FDA EPC text phrase is included in this document. For more information about how FDA determines the EPC Text Phrase, see the 2009 "Determining EPC for Use in the Highlights" guidance and 2013 "Determining EPC for Use in the Highlights" MAPP 7400.13.
    [Show full text]